The US Food and Drug Administration is starting off the summer with an array of approvals in historically less-active development areas like women’s health and obesity – along with the ninth novel oncologic of 2021, a new combination antipsychotic product with less of an irksome side effect, a novel smallpox drug intended for the national stockpile, and the first therapy for a rare genetic disorder.
The FDA opened June with approval of Scynexis, Inc.’s Brexafemme (ibrexafungerp), a triterpenoid antifungal for treatment of vulvovaginal candidiasis...
